The Impact of Drug Compounding on Pharma

Drug compounding meets unmet clinical needs, widens therapy choice and expands patient access to medicines. What are the lessons and opportunities for pharma?

Drug compounding is a fast growing sector meeting the needs of physicians and patients who are not well served by standardised pharmaceutical products. Driven by the growing trend towards personalized medicines and employing advanced formulation and drug delivery platforms, drug compounding companies are delivering for patients who cannot be treated with a regulatory approved product, or those needing specific formulations. In addition, they provide medicines that have been discontinued by the pharmaceutical manufacturer and play a crucial role in speciality medicines with short shelf lives which must be reconstituted prior to use.

Drug compounding is a progressive and engaged sector with a direct physician/patient relationship – what can pharma learn and what opportunities are there? In The Impact of Drug Compounding on Pharma, we interviewed leading drug compounding experts to help you understand the key touchpoints where industry can engage and benefit.

Experts explore the impact of drug compounding

Can compounding help to expand the therapeutic options available to treat patients. If so, what impact could this have on the future treatment of patients?
What might the impact on patient adherence and hospital readmission be for patients utilising compounded products?
Is current GMP legislation for compounding drugs sufficient and what areas might need to be addressed?
Is drug compounding really a value-added service that pharma should be engaged with?
What technological advances could help expand the repertoire of compounded drugs available in the future?
How might the expansion of biosimilars and novel delivery technologies impact drug compounding operators?
What will be the key drivers for the uptake of compounded medicines in the future?

What our experts say…

"For years people have underestimated compounding; they just thought it was compounding in a local pharmacy, however, all the intravenous mixtures, services in hospitals, the TPN [total parenteral nutrition] preparations, syringe mixtures that's all compounding. So when you pull everything into compounding, it's a multibillion dollar market, I think it's going to grow, especially as we get into more of the technology and pharmacogenomics for drug personalization."
Allen LV Jr

"One of the main drivers is for the personalized medicine. Compounding medicine is to personalize the medication to the patient plus we are expanding more into genetic-based disease like cancer and that is driving personalization. Also, it is a challenge with the allergic issues, for example, vancomycin, is a very important antibiotic that may cause red man syndrome if you infuse it very fast. When we compound vancomycin, we can control the amount infused per hour based on our eclipse or the pump to reduce the amount of red man syndrome for our patients."
Ramy Naguib Attia

"I see opportunities for compounding activities where the product shelf life is very short where you have to compound the product a couple of days or hours before the patient takes the drug. Another area for compounding is when doses need to be changed according to bodyweight. Drug compounding can help to expand treatment options, for instance in oncology, this is an important area of expansion."
Didier Colombeen

What to expect

A detailed report examining the activities and ambitions of drug compounding companies and how their work is impacting and influencing clinicians and patients
An examination of 5 key issues which pharma needs to understand
30 targeted questions put to drug compounding experts
Their perceptive responses that yielded 21 insights supported by 61 directly quoted comments

Expert contributors

The report harnesses critical insights and opinions of experts who identify the latest developments and future opportunities in drug compounding.

Loyd V Allen Jr. PhD. RPh., Editor-in-Chief for the International Journal of Pharmaceutical Compounding, Oklahoma, USA. CEO of the Midwest Institute of Research and Technology and Professor Emeritus of the University of Oklahoma College of Pharmacy.
Didier Colombeen, Former SVP, Head of Manufacturing and Supply Consumer Healthcare JV, GlaxoSmithKline, UK. He is a global pharma executive with considerable experience in manufacturing, supply chain and quality in the US, Europe and the emerging markets.
Ramy Naguib Attia, Ph.D., DPharm, General Manager & Director of Pharmacy, Leading Private Pharmacy, USA. He is a licensed Doctor of Pharmacy in Tennessee, Arkansas and Mississippi in USA and specialises in home infusion pharmacy, community pharmacy, and hospital pharmacy, and has extensive knowledge of different aspects of Biochemistry and Cell Biology.

Why Choose FirstWord FutureViews?

FirstWord FutureViews reports analyse in detail significant emerging technology and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lay ahead. These concise and highly focused reports:

Are based on primary research with experts whose knowledge and current experience is proven
Present clear expert insights free from secondary source information and spurious observations
Include only latest research and content; we don't reuse or recycle content

Contact Us

The Impact of Drug Compounding on Pharma

Browse by